Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 0.53 [0.31, 0.91]
1 study · 95 participants
Moderate

mTOR inhibitors vs chemotherapy/hormone therapy

Haematological toxicities ‐ Anaemia · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 1.42 [0.83, 2.44]
2 studies · 357 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Skin toxicities ‐ Mucositis · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 10.42 [1.34, 80.74]
2 studies · 357 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Respiratory toxicity ‐ Interstitial pneumonitis · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 7.36 [0.88, 61.52]
2 studies · 357 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Overall survival ‐ first‐line studies · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.32 [0.98, 1.78]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Overall survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.06 [0.7, 1.61]
1 study · 130 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Objective response rate: first‐line trial · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in objective response rate: first‐line trial compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 0.93 [0.75, 1.17]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Objective response rate: second/third‐line trials · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in objective response rate: second/third‐line trials compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 0.22 [0.01, 4.4]
1 study · 61 participants
Low

Light‐emitting diode (LED) irradiation vs standard dressing

Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Light‐emitting diode (LED) irradiation vs standard dressing

Change in wound size · ulceration and other skin changes caused by nerve damage in leprosy

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Light‐emitting diode (LED) irradiation vs standard dressing

Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Light‐emitting diode (LED) irradiation vs standard dressing

Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Light‐emitting diode (LED) irradiation vs standard dressing

Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Light‐emitting diode (LED) irradiation vs standard dressing

Cost of the intervention · ulceration and other skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Time to next isolation of PA · children (aged 1 to 12 years) with CF and a newly isolated PA infection

Summary of findings: cycled probably leads to higher time to next isolation of PA compared with culture‐based antibiotic therapy (moderate certainty).

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
HR 2.04 [1.28, 3.26]
1 study · 253 participants
Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

Quality of life · children (aged 1 to 12 years) with CF and a newly isolated PA infection

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Lung function: FEV1 mL (change from baseline) · children (aged 1 to 12 years) with CF and a newly isolated PA infection

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Very low

Summary of findings: cycled vs culture‐based antibiotic therapy

Pulmonary exacerbations · children (aged 1 to 12 years) with CF and a newly isolated PA infection

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

Time to chronic PA · children (aged 1 to 12 years) with CF and a newly isolated PA infection

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Adverse events: severe adverse events (total) · children (aged 1 to 12 years) with CF and a newly isolated PA infection

Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).

1 finding from 1 review

Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
RR 0.65 [0.39, 1.11]
1 study · 253 participants
Moderate